GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hana Pharm Co 293480.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

8,180

+0.86%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hana Pharm Co

Its shares trade on KRX under the ticker 293480.KS. It has been listed since 2 October 2018. In the fiscal year to 31 December 2025, it reported revenue of ₩239.50bn and net income of ₩8.78bn. At that date it held total assets of ₩418.14bn and shareholders' equity of ₩313.41bn.

Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
2 Oct 2018
Employees
703

Leadership

Pay as last reported

  • Mr. Yun Ha LeeChief Executive Officer, Director
  • Mr. Dong Hun ChoVice President, Director
  • Mr. Dong Yil YangVice President
  • Mr. Yong Yeon HwangManaging Director
  • Ms. Yeong Seon LeeManaging Director
  • Mr. Geun Hong MinManaging Director
  • Mr. Hong Jun ParkManaging Director
  • Mr. Hong Ju YoonAssistant Managing Director
  • Mr. Gye Nam ChoAssistant Managing Director
  • Yeong Su KimInternal Auditor
  • Mr. Jeong Wu LeeAssistant Managing Director
  • Mr. Yil Gi LeeAssistant Managing Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Hwaseong, Gyeonggi-Do with 703 employees
  • IPO in 2018-10-02 provides market access
  • Offers diverse pharmaceutical products including cardiovascular and analgesics

Weaknesses

  • No specific financial data provided for performance assessment
  • Limited product range details beyond listed categories
  • No mention of R&D investment or innovation capabilities

Opportunities

  • Growth potential in cardiovascular and gastrointestinal drug markets
  • Expansion opportunities in dermatology and anti-inflammatory segments
  • Potential for increased market share in pharmaceutical sector

Threats

  • Competition from other pharmaceutical companies in Korea
  • Regulatory challenges in drug manufacturing and approval
  • Dependence on specific product categories for revenue

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.